In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Ablation Frontiers LLC

Division of Medtronic PLC
www.ablationfrontiers.com

Latest From Medtronic Ablation Frontiers LLC

New Approaches To AF Ablation And Mapping

The market for atrial fibrillation catheter ablation devices continues to grow even as the field wrestles with basic questions and as new study results may dampen enthusiasm for some technologies. Though strategics dominate this sector, innovators with new approaches to ablation and mapping hope to help resolve unknowns and take a piece of this vast and underpenetrated market.

Market Intelligence Cardiovascular

The 2012 A-List: Investor Spotlight On Novartis, Versant

As part of START-UP’s annual Series A coverage, this year’s spotlight shines on the Novartis Venture Funds, the most active corporate group in biopharma company formation, and Versant Ventures, an unlikely device champion.

BioPharmaceutical Medical Device

Device Companies Follow New Map To Atrial Fibrillation

Device therapies for atrial fibrillation (AF) have so far failed to result in compelling efficacy across all types of disease and patients. The rates of elimination of AF following a catheter ablation procedure range from 30% to 80% according to the type of patient and the definition of success. The question of why success rates aren’t yet sufficient after a great deal of investment is an area of active pursuit, and one that opens up the door for next-generation AF device companies seeking to improve upon the results achieved to date.

Medical Device

Device Companies Follow New Map To Atrial Fibrillation

Three years ago, the FDA approved Johnson & Johnson’s ThermoCool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to devise new approaches.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ablation Frontiers Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Medtronic PLC
  • Senior Management
  • Keegan Harper, CEO
    Martin Chambers, VP, Sales & Mktg.
    Randy Werneth, VP, Research & Engineering
  • Contact Info
  • Medtronic Ablation Frontiers LLC
    Phone: (760) 438-4868
    6354 Corte Del Abeto
    Carlsbad, CA 92011
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register